If a Patient Develops TD with Vraylar: What Should Be Avoided
Avoid continuing or adding other dopamine receptor-blocking agents (DRBAs), particularly first-generation antipsychotics and metoclopramide, as these will worsen tardive dyskinesia and increase the risk of permanence. 1
Immediate Management Priorities
When tardive dyskinesia develops on Vraylar (cariprazine), the FDA label explicitly warns that tardive dyskinesia may become irreversible, and the risk increases with duration of treatment and cumulative dose 1. The syndrome can persist even after discontinuation of treatment 1.
Critical Medications to Avoid
Do NOT use anticholinergic agents (benztropine, trihexyphenidyl) if TD is present, as these medications can worsen tardive dyskinesia 2, 3. This is a common and dangerous pitfall—anticholinergics are appropriate for drug-induced parkinsonism but contraindicated when TD is the primary concern.
Avoid or discontinue:
- First-generation antipsychotics (haloperidol, fluphenazine, perphenazine) which carry the highest TD risk 2
- Metoclopramide and other dopamine-blocking antiemetics (prochlorperazine, promethazine) 4
- Any additional dopamine receptor-blocking agents 5
Treatment Algorithm
Step 1: Assess Clinical Situation
Continue Vraylar at current dose ONLY if the patient is in full remission AND any medication change would likely precipitate relapse 6. This is a narrow exception requiring careful clinical judgment.
Otherwise, proceed to Step 2.
Step 2: Modify Antipsychotic Regimen
- Lower the Vraylar dose if clinically feasible 6
- Consider switching to an antipsychotic with lower TD risk 6:
Note: While Vraylar is itself an atypical antipsychotic, the guidelines recommend switching to "another medication, most likely an atypical antipsychotic" when TD develops 6. The evidence suggests clozapine and quetiapine have particularly low TD risk profiles.
Step 3: Pharmacologic Treatment for Moderate-to-Severe TD
For moderate to severe or disabling TD, the APA strongly recommends treatment with VMAT2 inhibitors 7:
- Valbenazine
- Deutetrabenazine
These are FDA-approved specifically for TD and have the strongest evidence for efficacy 8, 3, 9.
Step 4: Alternative Agents (if VMAT2 inhibitors unavailable)
Second-line options with weaker evidence 5, 4:
- Amantadine (preferred over anticholinergics, especially if comorbid parkinsonism exists) 3
- Benzodiazepines (clonazepam)
- Levetiracetam
- Botulinum toxin for focal symptoms (tongue protrusion, blepharospasm) 10, 5
Critical Timing Consideration
Monitor for several weeks after any dose change or discontinuation because Vraylar has a very long half-life, causing plasma levels to accumulate over time 1. Adverse reactions, including TD, may first appear weeks after initiation or dose adjustment 1. This delayed onset means symptoms may worsen before improving even after appropriate intervention.
Common Pitfalls to Avoid
Do not abruptly stop Vraylar—gradual taper is preferred as abrupt cessation can cause withdrawal dyskinesia or exacerbate TD 6, 4
Do not treat with anticholinergics thinking you're addressing extrapyramidal symptoms—this worsens TD 2, 3
Do not assume all movement disorders are the same—differentiate TD (delayed onset, choreiform orofacial movements) from drug-induced parkinsonism (early onset, bradykinesia, rigidity) as treatments differ 3
Do not wait for spontaneous resolution in moderate-severe cases—the risk of permanence increases with time, and VMAT2 inhibitors should be started promptly 7, 8